Beta-Blockers After Heart Attack: New Research Findings

Beta-blockers have been a standard treatment for heart attack survivors for over 40 years. However, recent large-scale studies suggest that their benefits may not extend to all patients, particularly those with preserved heart function after a heart attack1 2. This evolving evidence challenges long-standing clinical practices and calls for a reassessment of beta-blocker use in the context of modern cardiac care1 3.

Beta-Blockers Show Limited Heart Attack Benefits

Beta-blockers are medications that reduce heart rate and blood pressure by blocking beta-adrenergic receptors, thereby decreasing the heart's oxygen demand and preventing arrhythmias4 5. Traditionally, they have been prescribed routinely after a myocardial infarction (heart attack) to improve survival and reduce the risk of recurrent cardiac events6 7. However, recent randomized trials have questioned the extent of their benefit in patients whose heart pumping function remains normal or only mildly impaired after a heart attack.

The REDUCE-AMI trial enrolled 5,020 patients with acute myocardial infarction (AMI) and preserved left ventricular ejection fraction (LVEF ≥50%) from Sweden, Estonia, and New Zealand8 2. Patients were randomized to receive either long-term beta-blocker therapy (metoprolol or bisoprolol) or no beta-blockers and were followed for an average of 3.5 years8 . The study found no significant difference in all-cause mortality (3.9% vs. 4.1%) or recurrent heart attacks (4.5% vs. 4.7%) between the beta-blocker and control groups8 . Rates of cardiovascular death, heart failure, and atrial fibrillation were also similar8 . These findings suggest that routine beta-blocker use may not provide meaningful clinical benefit in patients with preserved heart function after AMI8 2.

Similarly, the REBOOT trial, conducted in Spain and Italy with over 8,400 patients having LVEF ≥40%, showed no significant difference in the composite endpoint of death, reinfarction, or heart failure hospitalization between patients treated with beta-blockers and those who were not1 93. Notably, the trial highlighted that beta-blockers may no longer be necessary for the majority of patients with uncomplicated myocardial infarction and preserved cardiac function in the era of modern reperfusion and pharmacologic therapies1 9.

However, a meta-analysis combining data from four trials, including REBOOT, indicated that beta-blockers might benefit patients with mildly reduced LVEF (40–49%) by reducing the risk of death, new myocardial infarction, or heart failure by approximately 25% 1011. This suggests a potential subgroup of patients who could still derive advantage from beta-blocker therapy.

“If beta blockers do have an effect, it is probably small, given the other therapies we have.”

— Gregg Fonarow, University of California, Los Angeles12

Beta-blockers are known to cause side effects such as fatigue, low heart rate (bradycardia), sexual dysfunction, and mood changes, which can affect patient adherence and quality of life8 14. Avoiding unnecessary beta-blocker use in patients unlikely to benefit may reduce these adverse effects and improve overall well-being.

Key points on beta-blocker use after heart attack:

• Beta-blockers reduce heart rate and blood pressure by blocking beta-adrenergic receptors, lowering cardiac oxygen demand4 5.
• Routine long-term beta-blocker therapy did not significantly reduce mortality or major cardiovascular events in patients with preserved LVEF after AMI8 2.
• Patients with mildly reduced LVEF (40–49%) may benefit from beta-blockers, with reduced risk of death, reinfarction, or heart failure10 11.
• Side effects of beta-blockers include fatigue, bradycardia, sexual dysfunction, and mood disorders8 14.
• Modern reperfusion and pharmacologic treatments have improved outcomes, possibly diminishing the incremental benefit of beta-blockers in certain patients1 2.

“Patients post-MI with mildly reduced LVEF (40-49%) but without HF represent a sizeable population. While it is intuitive to argue that these patients benefit from beta-blockers in a similar way as patients with reduced LVEF (<40%), there have been no specific randomised trials.”

— Xavier Rosselló, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Son Espases University Hospital10

Study Limitations and Considerations

While the recent trials provide important insights, several limitations and considerations should be noted when interpreting the findings.

The REDUCE-AMI trial was an open-label study, meaning both patients and doctors knew the treatment assignments, which could introduce bias. However, researchers believe this did not substantially affect hard clinical outcomes such as death or recurrent heart attacks8 . The majority of participants were from Sweden, which may limit the generalizability of the results to other populations or healthcare settings8 .

The REBOOT trial also had an open-label design and was conducted primarily in Spain and Italy1 9. Although it included a large and diverse patient population, the findings may not apply universally, especially in regions with different standards of care or patient demographics1 .

A notable finding from REBOOT was the increased risk of adverse outcomes in women treated with beta-blockers compared to women not receiving them, particularly among those with preserved LVEF13 . This sex-specific effect was not observed in men and may relate to differences in beta-blocker metabolism, heart size, or dosing13 . Women generally have smaller left ventricular cavities and higher plasma concentrations of beta-blockers at equivalent doses, which could contribute to these outcomes13 . These findings underscore the importance of sex-specific analyses in clinical trials and suggest that beta-blocker therapy may need to be tailored accordingly13 .

The meta-analysis indicating benefit in patients with mildly reduced LVEF (40–49%) was based on a smaller subgroup and combined data from multiple trials with varying protocols10 . Further research is needed to confirm these benefits and to clarify the optimal patient selection and dosing.

Advances in reperfusion therapy, such as rapid coronary artery stenting, and improved secondary prevention with potent antiplatelet agents and statins have dramatically reduced the extent of heart muscle damage and complications after AMI1 2. These improvements may explain why beta-blockers, which were highly beneficial in the pre-reperfusion era, show diminished effects in contemporary practice1 2.

Summary of study limitations and considerations:

• Open-label design in major trials may introduce bias but likely does not affect mortality or major event outcomes8 1.
• Predominance of European populations in trials may limit applicability to other regions8 1.
• Increased risk of adverse outcomes with beta-blockers observed in women with preserved LVEF requires further investigation13 .
• Benefits of beta-blockers in mildly reduced LVEF patients need confirmation through additional research10 .
• Modern reperfusion and pharmacologic therapies have changed the clinical landscape, potentially reducing beta-blocker benefits1 2.

“This trial will reshape all international clinical guidelines. It joins other previous landmark trials led by CNIC and Mount Sinai that have already transformed some global approaches to cardiovascular disease.”

— Valentin Fuster, MD, PhD, Mount Sinai Fuster Heart Hospital and Centro Nacional de Investigaciones Cardiovasculares (CNIC) 1

Table 1: Summary of Key Beta-Blocker Trials in Post-Myocardial Infarction Patients with Preserved or Mildly Reduced LVEF